Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

CureVac (CVAC) Total Non-Current Liabilities (2019 - 2025)

Historic Total Non-Current Liabilities for CureVac (CVAC) over the last 7 years, with Q3 2025 value amounting to $36.5 million.

  • CureVac's Total Non-Current Liabilities fell 542.18% to $36.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $36.5 million, marking a year-over-year decrease of 542.18%. This contributed to the annual value of $36.2 million for FY2024, which is 6038.6% down from last year.
  • As of Q3 2025, CureVac's Total Non-Current Liabilities stood at $36.5 million, which was down 542.18% from $39.0 million recorded in Q2 2025.
  • CureVac's Total Non-Current Liabilities' 5-year high stood at $182.7 million during Q2 2021, with a 5-year trough of $36.1 million in Q1 2025.
  • Its 5-year average for Total Non-Current Liabilities is $102.3 million, with a median of $100.0 million in 2023.
  • The largest annual percentage gain for CureVac's Total Non-Current Liabilities in the last 5 years was 10337978.85% (2021), contrasted with its biggest fall of 8054.05% (2021).
  • CureVac's Total Non-Current Liabilities (Quarter) stood at $128.2 million in 2021, then surged by 36.12% to $174.5 million in 2022, then crashed by 47.63% to $91.4 million in 2023, then plummeted by 60.39% to $36.2 million in 2024, then grew by 0.84% to $36.5 million in 2025.
  • Its Total Non-Current Liabilities stands at $36.5 million for Q3 2025, versus $39.0 million for Q2 2025 and $36.1 million for Q1 2025.